[
    {
        "title": "Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. New England Journal of Medicine. 2014;370(25):2377.",
        "paper_uid": "456cb129",
        "reference": "Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. New England Journal of Medicine. 2014;370(25):2377.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.",
        "paper_uid": "1fbf0f4e",
        "reference": "Maneiro JR. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. [Review]. Seminars in Arthritis & Rheumatism. 2017;47(2):149.",
        "save_folder_path": null,
        "study_design": "SYSTEMATIC_REVIEW"
    }
]